Intech Biopharm Ownership

6461 Stock  TWD 23.95  0.05  0.21%   
Intech Biopharm has a total of 116.96 Million outstanding shares. Intech Biopharm secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Intech Biopharm. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Intech Stock Ownership Analysis

About 47.0% of the company shares are owned by insiders or employees . The book value of Intech Biopharm was presently reported as 9.61. The company recorded a loss per share of 2.87. Intech Biopharm had not issued any dividends in recent years. For more info on Intech Biopharm please contact the company at 886 2 7721 8877 or go to https://www.intechbiopharm.com.

Intech Biopharm Outstanding Bonds

Intech Biopharm issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Intech Biopharm uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Intech bonds can be classified according to their maturity, which is the date when Intech Biopharm has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Pair Trading with Intech Biopharm

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Intech Biopharm position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Intech Biopharm will appreciate offsetting losses from the drop in the long position's value.

Moving together with Intech Stock

  0.724743 Oneness BiotechPairCorr

Moving against Intech Stock

  0.656547 Medigen Vaccine BiologicsPairCorr
  0.642881B Fubon Financial HoldingPairCorr
  0.622882B Cathay Financial HoldingPairCorr
  0.62881A Fubon Financial HoldingPairCorr
  0.482882A Cathay Financial HoldingPairCorr
The ability to find closely correlated positions to Intech Biopharm could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Intech Biopharm when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Intech Biopharm - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Intech Biopharm to buy it.
The correlation of Intech Biopharm is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Intech Biopharm moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Intech Biopharm moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Intech Biopharm can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Intech Stock Analysis

When running Intech Biopharm's price analysis, check to measure Intech Biopharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intech Biopharm is operating at the current time. Most of Intech Biopharm's value examination focuses on studying past and present price action to predict the probability of Intech Biopharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intech Biopharm's price. Additionally, you may evaluate how the addition of Intech Biopharm to your portfolios can decrease your overall portfolio volatility.